BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30638778)

  • 1. Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation.
    Zuo L; Lv Y; Wang Q; Yin Z; Wang Z; He C; Guo W; Niu J; Bai W; Li K; Yu T; Yuan X; Chen H; Liu H; Xia D; Wang E; Luo B; Li X; Yuan J; Han N; Nie Y; Fan D; Han G
    J Vasc Interv Radiol; 2019 Feb; 30(2):148-153.e2. PubMed ID: 30638778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
    Nardelli S; Riggio O; Marra F; Gioia S; Saltini D; Bellafante D; Adotti V; Guasconi T; Ridola L; Rosi M; Caporali C; Fanelli F; Roccarina D; Bianchini M; Indulti F; Spagnoli A; Merli M; Vizzutti F; Schepis F
    J Hepatol; 2024 Apr; 80(4):596-602. PubMed ID: 38097113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests.
    Berlioux P; Robic MA; Poirson H; Métivier S; Otal P; Barret C; Lopez F; Péron JM; Vinel JP; Bureau C
    Hepatology; 2014 Feb; 59(2):622-9. PubMed ID: 24620380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of mortality and overt hepatic encephalopathy undergoing transjugular intrahepatic portosystemic shunt: a retrospective cohort study.
    Li K; Cheng Y; Zhao R; Jiang H; Zhang L; Tong Y; Li S
    Abdom Radiol (NY); 2024 Mar; 49(3):908-918. PubMed ID: 37957372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.
    Chen R; Luo L; Zhang YZ; Liu Z; Liu AL; Zhang YW
    World J Gastroenterol; 2024 Apr; 30(13):1859-1870. PubMed ID: 38659484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain regional homogeneity changes following transjugular intrahepatic portosystemic shunt in cirrhotic patients support cerebral adaptability theory--a resting-state functional MRI study.
    Ni L; Qi R; Zhang LJ; Zhong J; Zheng G; Wu X; Fan X; Lu GM
    Eur J Radiol; 2014 Mar; 83(3):578-83. PubMed ID: 24299611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Mortality and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Placement: Baseline and Longitudinal Body Composition Measurement.
    Tuifua TS; Kapoor B; Partovi S; Shah SN; Bullen JA; Enders J; Laique S; Levitin A; Gadani S
    J Vasc Interv Radiol; 2024 May; 35(5):648-657.e1. PubMed ID: 38244917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
    Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in cerebral blood flow after transjugular intrahepatic portosystemic shunt can help predict the development of hepatic encephalopathy: an arterial spin labeling MR study.
    Zheng G; Zhang LJ; Wang Z; Qi RF; Shi D; Wang L; Fan X; Lu GM
    Eur J Radiol; 2012 Dec; 81(12):3851-6. PubMed ID: 22832118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.
    Bai M; Qi XS; Yang ZP; Yang M; Fan DM; Han GH
    World J Gastroenterol; 2014 Mar; 20(10):2704-14. PubMed ID: 24627607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.
    Saad WE; Darwish WM; Davies MG; Waldman DL
    J Vasc Interv Radiol; 2010 Feb; 21(2):218-23. PubMed ID: 20123207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial.
    Chen L; Xiao T; Chen W; Long Q; Li R; Fang D; Wang R
    Liver Int; 2009 Aug; 29(7):1101-9. PubMed ID: 19386025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis.
    Dhanasekaran R; West JK; Gonzales PC; Subramanian R; Parekh S; Spivey JR; Martin LG; Kim HS
    Am J Gastroenterol; 2010 Mar; 105(3):635-41. PubMed ID: 19904245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement.
    Borentain P; Soussan J; Resseguier N; Botta-Fridlund D; Dufour JC; Gérolami R; Vidal V
    Diagn Interv Imaging; 2016 Jun; 97(6):643-50. PubMed ID: 26947721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.
    Gaba RC; Couture PM; Bui JT; Knuttinen MG; Walzer NM; Kallwitz ER; Berkes JL; Cotler SJ
    J Vasc Interv Radiol; 2013 Mar; 24(3):411-20, 420.e1-4; quiz 421. PubMed ID: 23312989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.
    Ascha M; Hanouneh M; S Ascha M; Zein NN; Sands M; Lopez R; Hanouneh IA
    Dig Dis Sci; 2017 Feb; 62(2):534-542. PubMed ID: 27154510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
    Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
    Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
    Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
    Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Liver Failure after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis with Model for End-Stage Liver Disease Score of 12 or Less: Incidence, Outcome, and Prognostic Factors.
    Luca A; Miraglia R; Maruzzelli L; D'Amico M; Tuzzolino F
    Radiology; 2016 Aug; 280(2):622-9. PubMed ID: 26982564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.